Press Note

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC

Lupin wins India Packaging Award for 'Corcal Bone & Beauty'

Mumbai, May 29, 2019: Pharma major Lupin Limited (Lupin) announced today that it has won the **India Packaging Award 2019** for its Consumer Healthcare brand 'Corcal Bone & Beauty', a calcium supplement specially for women. Corcal is the latest launch by the company's Consumer Healthcare Business, LupinLife. The India Packaging Award was received for the category '**Excellence in Packaging Design - Graphics and Brand Value Add'** by UBM India.

Speaking on the win **Mr. Anil V. Kaushal, Head - LupinLife Consumer Healthcare, Lupin Limited** said, *"We would like to thank the jury of 'India Packaging Award 2019' for recognising our efforts in making the packaging appealing and convenient for our customers. The packaging of Corcal Bone & Beauty has been specifically designed to create a visual appeal basis rigorous consumer research. For us, winning the award is a great honor and it demonstrates our level of commitment to excellence and design while keeping in mind quality, safety and compliance requirements."*

About Corcal Bone & Beauty

LupinLife's Corcal Bone & Beauty contains natural Coral Calcium and over 70 trace minerals like Zinc, Selenium, Gold, Magnesium, and Silica. The product helps maintain healthy skin, hair, nails & teeth and strong bones.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Dec 2018, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Dec 2018, Bloomberg LTM); 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).

For the financial year ended 31st March 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

Press Note

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66408237

Safe Harbor Statement